APEIRON Biologics AG

Improving the lives of patients with next generation therapies against respiratory disease and cancer. Currently developing a treatment for advanced COVID-19.

[APEIRON Biologics AG @apeironbio]

Congrats to R. Guggenberger, G. Wirnsberger and APEIRON Biologics founder Prof. Penninger. They report that all SARS-CoV-2 variants analyzed, including #VOC such as #Omicron, exhibit enhanced binding affinity to clinical grade #APN01.

[EMBO Mol. Medicine @EmboMolMed]

📢Clinical grade #ACE2 as a universal agent to block #SARSCoV2 variants

By G. Wirnsberger, J. Penninger & colleagues @karolinskainst @invIOs_com @IMBA_Vienna @ubclifesciences

👉Fully #openaccess: https://t.co/PpZCiJJAOc

[invIOs @invIOs_com]

.@apeironbio shareholders approve new group structure geared towards enabling innovation and growth:
invIOs becomes fully separate entity focused on advancing its unique #EPiC cell therapy platform and clinical-stage immuno-oncology pipeline https://t.co/KJE7ZWKfiM

[invIOs @invIOs_com]

We are excited to join #BIOEuropeSpring for the first time with invIOs and to connect at this global meeting organized by @EBDgroup. E-meet us next week and learn more about invIOs' innovation hub and our unique approach to #cell_therapy.
https://t.co/FKT0osIwi3

[invIOs @invIOs_com]

Join us tomorrow at Sachs European Life Sciences CEO Forum if you want to learn about our approach towards individualized cancer treatment! Do not miss our Spotlight Showcase tomorrow Tuesday, March 1st at 3:40 pm CET.
#Sachs_ELSF #lifesciences

[invIOs @invIOs_com]

#News: invIOs (innovative Immuno-Oncology) GmbH is pleased to announce it will commence operations on 1 January 2022.
Read more: https://t.co/N1JUPX3Xfj
#newcompany #CancerResearch

[invIOs @invIOs_com]

Mario is Lead Scientist at invIOs and mainly responsible for INV441, our TILs project.

#team #cancerresearch #immunooncology #biotech #FacesOfInvios

[invIOs @invIOs_com]

Meet Andreas, Head of IT at invIOs. #Team #cancerresearch #biotech #FacesOfInvios

[invIOs @invIOs_com]

Romana is Chief Medical & Scientific Officer at invOs and responsible for the development of our drug candidate projects.

#team #cancerresearch #immunooncology #passionforwork #biotech

[invIOs @invIOs_com]

Only 5 days until invIOs goes live. Our todays face of invIOs is Alexander, Head of Research & Preclinical Development. Together with his team, he is responsible for the development of our immuno oncology therapeutics.
#cancerresearch #immunooncology #team #biotech

[Johannes Stadlmann @JohStadlmann]

Removing the N-glycans of hACE2 increases its binding strength to Spike and makes it a better SARS-CoV-2 interceptor: https://t.co/c9IHVYtji4
Grand collaboration between @boku, @mms_boku, @biotop_phd, @penningerlab, @imba_vienna, @ubc, @apeironbio, @medunigraz, @karolinskainst

[APEIRON Biologics AG @apeironbio]

#News: @invIOs_com a fully owned subsidiary of APEIRON Biologics AG is pleased to announce it will commence operations on 1 January 2022.
Read more: https://t.co/CERTZwpwMR
#newcompany #CancerResearch

[Die Presse @DiePressecom]

Bei der Führung weder Scheu noch Scheuklappe haben sei entscheidend, sagt Romana Gugenberger, Vorständin für Forschung und Entwicklung beim Biotech-Unternehmen Apeiron. https://t.co/LwuN94JG0e

[APEIRON Biologics AG @apeironbio]

#Job: Looking for a challenge at the intersection of Science and Business? We are currently recruiting a (Junior) Legal Counsel. Join a highly motivated team with high ambitions.
Find our more: https://t.co/okYRXuafRr
#HIRINGNOW #legal #Science #lifesciences

[Drug Discovery World @DDWJournal]

@apeironbio has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.

https://t.co/Cqi4e0gfJp

#Covid19

[APEIRON Biologics AG @apeironbio]

Follow us on The Cancer Revolution. Read on characteristics which cancer cells acquire during the development of tumors. Learn more on challenges ahead for cancer therapy.
https://t.co/LQk9JjbJnq

#Cancer #Oncology #CancerResearch #CancerAwareness

[APEIRON Biologics AG @apeironbio]

#News: APEIRON Biologics today announced the start of a company sponsored Phase 1 clinical #COVID19 trial for inhalation of APN01. Primary objective is to evaluate safety and tolerability of inhaled APN01. Read more:
https://t.co/hMcGiYlHhT
#covid19therapy #SARSCoV2 #inhalation

[APEIRON Biologics AG @apeironbio]

We have discussed the role of #ACE2 within the RAAS and the #therapeutical potential of a recombinant soluble ACE2 for COVID-19 patients with Prof. Josef Penninger.
Read here our 3 Questions to Prof. Josef Penninger: https://t.co/PbqylQKqyM

#COVID19 #SARSCoV2 #3Questions2

[APEIRON Biologics AG @apeironbio]

Congratulations to @eusapharma and @BeiGeneGlobal for reaching this major milestone. QARZIBA® (Dinutuximab Beta) is now approved in #China for the treatment of high-risk #neuroblastoma in patients aged 12 months and above.
#immunotherapy #cancer

[APEIRON Biologics AG @apeironbio]

Congratulations to @eusapharma and @BeiGeneGlobal for reaching this major milestone. QARZIBA® (Dinutuximab Beta) is now approved in #China for the treatment of high-risk #neuroblastoma in patients aged 12 months and above.
#immunotherapy #cancer

[BeOne Medicines @BeOneMedicines]

We’re pleased to announce approval in China for the treatment of high-risk neuroblastoma in patients aged 12 months and above. This approval reflects our commitment to improving access to medicines worldwide.

[APEIRON Biologics AG @apeironbio]

Did you ever wonder how computational techniques allow to study the effects of #mutations of #SARSCoV2? This time we have asked our #3Questions2 to Prof. Chris Oostenbrink. @mms_boku
Read more: https://t.co/DOmmogoFGx
#COVID19 #Variant #Science #computationalscience